ZBED1: A Potential Drug Target and Biomarker (G9189)

Target Name: ZBED1

NCBI ID: G9189

ZBED1

ZBED1: A Potential Drug Target and Biomarker

Zinc finger proteins (ZFPs) are a family of non-coding RNAs that play a crucial role in gene regulation and are involved in various cellular processes. One of the ZFPs, ZBED1 (Zinc Finger Enhancer-Binding Element), has been identified as a potential drug target and biomarker. In this article, we will explore the biology of ZBED1 and its potential as a drug target.

The Zinc Finger Gene

Zinc finger proteins are characterized by the presence of a zinc finger motif, which consists of a specific arrangement of amino acids that consists of a central zinc atom, a variable number of basic amino acids, and a C-terminal hypervariable region (HVR). The Zinc Finger motif is a conserved element that is found in various organisms, including humans.

ZBED1, a Zinc Finger Enhancer-Binding Element

ZBED1 is a Zinc Finger gene that is located on chromosome 16 and encodes for a protein of approximately 21 kDa. The ZBED1 gene has a unique structure that consists of a single exon and a splice variant that is expressed in the brain, heart, and testes.

The ZBED1 protein

The ZBED1 protein is a key regulator of gene expression and has been involved in various cellular processes. One of the most significant functions of ZBED1 is its ability to enhance the activity of RNA polymerase II (RNA-II), which is responsible for transcribing DNA into RNA.

ZBED1 has been shown to play a role in the regulation of gene expression by RNA-II. Studies have shown that ZBED1 can bind to the active site of RNA-II and enhance its activity. This enhancement of RNA-II activity can lead to the translation of specific genes and can be a potential drug target.

The Potential Drug Target

The potential drug target for ZBED1 is its role in the regulation of gene expression by RNA-II. By enhancing the activity of RNA-II, ZBED1 can promote the translation of specific genes and can be a target for drugs that are designed to inhibit or modulate RNA-II activity.

ZBED1 has also been shown to play a role in the regulation of cellular processes that are important for the development and progression of cancer. For example, studies have shown that ZBED1 can promote the growth and survival of cancer cells. This suggests that ZBED1 may be a useful biomarker for the development and progression of cancer.

The Potential Biomarker

In addition to its potential as a drug target, ZBED1 has also been identified as a potential biomarker for the diagnosis and prognosis of cancer. Studies have shown that ZBED1 levels are elevated in various types of cancer, including breast, ovarian, and colorectal cancers.

The increased expression of ZBED1 in cancer cells may be a sign of the disease progression and can be used as a biomarker for the diagnosis and prognosis of cancer. This suggests that ZBED1 may be a useful tool for the development of new cancer diagnostics and therapies.

Conclusion

ZBED1 is a Zinc Finger gene that has been shown to play a role in the regulation of gene expression by RNA-II and has the potential as a drug target and biomarker. The enhanced activity of ZBED1 in the regulation of RNA-II and its potential as a cancer biomarker make it an attractive target for further research. Further studies are needed to fully understand the biology of ZBED1 and its potential as a drug and biomarker.

Protein Name: Zinc Finger BED-type Containing 1

Functions: Functions as an E3-type small ubiquitin-like modifier (SUMO) ligase which sumoylates CHD3/Mi2-alpha, causing its release from DNA (PubMed:27068747). This results in suppression of CHD3/Mi2-alpha transcription repression, increased recruitment of RNA polymerase II to gene promoters and positive regulation of transcription including H1-5 and ribosomal proteins such as: RPS6, RPL10A, and RPL12 (PubMed:12663651, PubMed:17209048, PubMed:17220279, PubMed:27068747). The resulting increased transcriptional activity drives cell proliferation (PubMed:12663651, PubMed:17220279). Binds to 5'-TGTCG[CT]GA[CT]A-3' consensus sequences in gene promoters of ribosomal proteins (PubMed:12663651, PubMed:17209048, PubMed:17220279, PubMed:27068747)

The "ZBED1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ZBED1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets